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Abstract  
BACKDROUND: Ovarian carcinoma is a leading cause of death in gynecological malignancy. 
Ovarian surface epithelial serous and mucinous tumours are classified as benign, borderline, and 
malignant. The identification of borderline tumours most likely to act aggressively remains an 
important clinical issue.  
AIM: This work aimed to study DNA ploidy and nuclear area in ovarian serous and mucinous; 
benign, borderline and malignant tumours. 
MATERIAL AND METHODS: This study included forty ovarian (23 serous and 17 mucinous) 
tumours. Paraffin blocks were sectioned; stained with haematoxylin and eosin for histopathologic 
and morphometric studies and with blue feulgen for DNA analysis. 
RESULTS: All four serous and six out of nine mucinous benign tumours were diploid. All eight 
serous and five mucinous malignant tumours were aneuploid. Nine of eleven (81.8%) serous and 
all three mucinous borderline tumours were aneuploid. There were highly significant differences in 
mean aneuploid cells percentage between serous benign (1.5%), borderline (45.6%) and malignant 
(74.5%) (p = 0.0001) and between mucinous benign (13.2%) and both borderline (63.7%) and 
malignant (68.4%) groups (p = 0.0001).There were significant differences in nuclear area between 
serous benign (26.191%), borderline (45.619%) and malignant (67.634 %) and a significant positive 
correlation between mean percentage aneuploid value and mean nuclear area in all serous and 
mucinous groups. 
CONCLUSION: We suggest that DNA ploidy and nuclear area combined, may be adjuncts to 
histopathology; in ovarian serous and mucinous benign, borderline and malignant neoplasms; 
identifying the aggressive borderline tumours. 
 
 
 
 
Introduction 
 
Ovarian carcinoma is one of the leading 
causes of death in patients with gynecological 
malignancy all over the world, representing about 30% 
of all carcinomas of the female genital organs [1]. 
Surface epithelial carcinomas constitute about 90% of 
all ovarian carcinomas. Borderline ovarian tumors 
account for 15-20% of all ovarian epithelial tumors [2].  
Typically this cancer has an insidious onset, 
and worse prognosis, consequently 70% of women 
present with disease that has spread beyond the 
ovary, resulting in a high mortality rate despite optimal 
surgery and aggressive chemotherapy [3]. Hence, the 
discovery of ways to diagnose ovarian cancer at an 
early stage and establish more effective therapies is a 
critical and urgent issue [4]. 
In Egypt, tumours of the female genital 
system represent 4.1% of total malignancies, ovarian 
cancer representing 1.37% of them. Surface epithelial 
tumors represent 73.33% of ovarian tumors. Serous 
cystadenocarcinoma represents 34.82% and 
mucinous cystadenocarcinoma represents 17.04% of 
them, referred to hospital-based cancer registry of 
National Cancer Institute (N.C.I) in Egypt during the 
years 2003-2004 [5]. 
Ovarian surface epithelial tumours are 
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classified into the following histological subtypes: 
serous, mucinous, endometrioid, clear cell, transitional 
cell, squamous, mixed, and undifferentiated [6]. 
Usually each subtype can be classified as benign, 
borderline, and malignant [7]. Patients with borderline 
tumours have an excellent prognosis, but five-year 
survival rates for patients with advanced stage 
cancers are less than 25% [8]. 
Histological type of ovarian cancer is one of 
the major prognostic factors determining clinical 
outcome. Poorly differentiated tumors are 
characterized by high metastatic rate and 
aggressiveness that influence the treatment outcome 
[9]. 
Borderline tumours show some of the features 
of ovarian carcinomas (nuclear atypia, high mitotic 
activity, stratification, glandular complexity, branching 
and papillary fronds) but they lack stromal invasion. 
However, it is important to separate borderline 
tumours from their invasive counterparts because of 
their superior prognosis [10]. 
Although most patients with borderline 
tumours can be cured by surgical excision and 
majority of patients with borderline ovarian tumours 
have an excellent prognosis, apparently 15% may 
suffer from recurrence and die from disease [11].  
The identification of patients most likely to 
suffer recurrence after primary surgical treatment 
remains an important clinical issue. Investigations into 
relationship between tumor recurrence and histologic 
subtype, cytologic atypia and invasiveness of 
extraovarian implants had lead to inconsistent results. 
This inconsistency may be partly due to qualitative 
parameters being difficult to reproduce [12]. DNA 
cytometry may supplement subjective morphologic 
grading by providing objective and reproducible 
prognostic indices [13]. 
Independent prognostic factors in patients 
with epithelial ovarian borderline tumors are DNA-
ploidy, international FIGO-stage, histologic type and 
patient 's age. Studies on other molecular markers 
have not yet uncovered a reliable prediction of 
biologic behaviour; however, there is hope that future 
studies of genetics and molecular biology of these 
tumors will lead to useful laboratory test [14, 15].  
Histologic grading is very important for 
treatment decisions in ovarian cancer. All grading 
systems contain a significant subjective component, 
which could be reduced by including objective 
measurements into the diagnostic decision. Image 
analysis was used to determine nuclear area and 
ploidy distributions in patients with epithelial ovarian 
cancer. The number of nuclei with very high DNA 
content was found to be of prognostic importance. 
Image analysis thus provides additional prognostic 
information in epithelial ovarian cancer [16]. 
DNA ploidy and/or S-phase fraction have 
been used as biologic predictors of aggressive 
behaviour in a variety of solid tumours [17]. Recently, 
attention has focused on borderline lesions to 
determine if flow cytometry plays a role in separating 
potentially aggressive tumours from those which will 
pursue a more innocuous course [18, 19]. 
This study aims to study cytometric DNA 
ploidy and morphometric nuclear area in ovarian 
serous and mucinous; benign, borderline and invasive 
malignant epithelial tumours. 
 
 
Material and Methods 
 
The material of this study consisted of 40 
ovarian specimens from patients having surface 
epithelial ovarian serous and mucinous tumours. 
Material was obtained from pathology department, 
Kasr el Eini Hospital, Cairo University. Formalin fixed, 
paraffin - embedded tissue blocks were obtained from 
specimens. Each specimen was fixed in 10% buffered 
formalin and routinely processed in ascending grades 
of alcohol and xylene to be embedded in paraffin 
blocks. Two sections, 4 µm thick each, were cut from 
each block. One section was stained with 
Haematoxylin and Eosin (H&E) for routine 
histopathologic typing, grading and for morphometric 
study. The other section was stained with blue feulgen 
stain for DNA analysis.  
The nuclear morphometry and DNA analysis 
were performed at the Pathology Department, 
National Research Center using the Leica Qwin 500 
Image Analyzer (LEICA Imaging Systems Ltd, 
Cambridge, England).  
 
Nuclear Morphometric Analysis 
The morphometric analysis was carried out 
with optical magnification of 400X on the routine 
haematoxylin and eosin stained slides. The nuclear 
area was measured in micrometers of a real- time 
image from the microscope that was visualized on the 
video monitor. 100-150 intact nuclei have been 
measured. These nuclei were selected randomly from 
representative regions in different fields. 
 
DNA Analysis 
Touching" nuclei were "Cut" from each other, 
and cellular fragments or extraneous cells were 
erased prior to DNA measurements. Only separate, 
intact nuclei were measured. Distorted or overlapping 
nuclei and nuclear fragments were manually 
eliminated from measurement. The optical density of 
the selected nuclei in each microscopic field was then 
measured and automatically converted by the system 
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into DNA content. Many fields were selected until the 
desired number of nuclei 100 - 150 had been 
measured. The results were displayed as a frequency 
histogram generated by plotting the DNA content 
versus the number of nuclei counted. The 
percentages of cells within each selected area were 
calculated and determined automatically by the 
system. Interpretation of DNA histograms was 
performed according to [20]. 
 
Statistical analysis 
Statistical analysis of the results was 
performed using the chi-square test and Z test with a 
P value set as < 0.05 to indicate significance. 
 
 
Results 
 
Forty specimens of selected ovarian tumour 
cases were prospectively collected. 23 cases (57.5%) 
were serous and 17cases (42.5%) were mucinous 
tumors. Ovarian tumours included 13 cases of benign 
cystadenomas (4 serous & 9 mucinous), fourteen 
cases of borderline tumours (11 serous & 3 mucinous) 
and thirteen cases of cysadenocarcinomas (8 serous 
& 5 mucinous).  
Table 1: Histopathological diagnosis of the studied cases 
% No. of cases Diagnosis 
10 4 Serous benign  
27.5 11 Serous borderline  
20 8 Serous malignant  
22.5 9 Mucinous benign  
7.5 3 Mucinous borderline  
12.5 5 Mucinous malignant  
100 40 Total 
 
The age of the cases ranged between 21 and 
75 years with a mean age of 48 years.  
 
Figure 1: Pie chart showing percentage of studied cases 
 
All serous and six out of nine mucinous 
benign tumours were diploid. Only two out of eleven 
serous and none of the mucinous borderline tumours 
were diploid. All serous and mucinous malignant 
tumours were aneuploid. 
A) 
 
D)
 
B)
 
E)
 
C)
 
F)
 
Figure 2:  A) Benign serous cystadenoma lined by single layer of 
bland-looking nonstratified cuboidal to columnar epithelial cells, 
(H&E, x 400). B)  Borderline serous tumor showing thick papillae 
lined by stratified cuboidal to columnar cells with mild nuclear atypia 
(H&E, x 400). C) Serous cystadenocarcinoma showing areas of 
stromal invasion (H&E, x 200). D) Benign mucinous cystadenoma 
showing nonstratified columnar epithelium with abundant, pale-
staining intracellular mucin and small, basal nuclei (H&E, x 400). E)  
Borderline mucinous tumor showing papillary infoldings lined by 
stratified epithelium with thin central stromal cores (H&E, x 100). F) 
Mucinous cystadenocarcinoma showing marked cytological atypia 
(H&E, x 400) 
 
 
Highly significant differences between benign 
and both of borderline and malignant serous lesions 
were found for the percentage of diploid cells (P value 
< 0.05).  
Highly significant differences between benign 
and both of borderline and malignant mucinous 
lesions were found for the percentage of diploid cells 
(P value < 0.05).  
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a)  b)  c)  
d)  e)  f)  
Figure 3: a) Serous benign tumor with diploid histogram. b) Serous borderline tumor with diploid peak and few aneuploid cells. c) Serous 
malignant tumor with aneuploid histogram. d) Mucinous benign tumor with diploid histogram. e) Mucinous borderline tumor with aneuploid 
histogram. f) Mucinous malignant tumor with almost aneuploid cells 
 
Highly significant differences between benign, 
borderline and malignant lesions were found for the 
percentage of aneuploid cells in serous tumours (>4c) 
(p = 0.0001). 
Table 2: Classification of studied cases according to DNA 
cytometry 
Diagnosis No. of cases Diploid cases Tetraploid 
cases 
Aneuploid 
cases 
Serous benign 4 (10%) 4 (10%) - - 
Serous borderline 11 (27.5%) 2 (5%) - 9 (22.5%) 
Serous malignant 8 (20%) - - 8 (20%) 
Mucinous benign 9 (22.5%) 6 (15%) 3(7.5%) - 
Mucinous borderline 3 (7.5%)  - 3 (7.5%) 
Mucinous malignant 5 (12.5%)  - 5 (12.5%) 
Total 40 (100%) 15 (30%) 3 (7.5%) 28 (62.5%) 
 
There is highly significant difference in the 
aneuploid value between benign and both borderline 
and malignant groups in mucinous tumours. Also, 
aneuploid value was greater in malignant than in 
borderline mucinous tumours, though none 
statistically significant. 
Table 3: Mean diploid (2C) cell percentage in serous lesions 
Diagnosis Mean% Std. Deviation Std. error Range 
Benign 64.172 22.100 11.050 31.6-80.0 
Borderline 6.231 7.148 2.155 0.0-18.8 
Malignant 3.294 8.589 3.036 0.0-24.4 
 
There is significant difference in the nuclear 
area between benign, borderline and malignant 
groups in serous tumours. 
 There is significant difference in the 
nuclear area between benign and malignant mucinous 
groups. Also, nuclear area was greater in mucinous 
malignant tumours than in borderline mucinous 
tumours; though not statistically significant and there 
were differences in nuclear area between borderline 
and both benign and malignant mucinous groups, 
though not statistically significant. 
Table 4: Mean diploid (2C) cell percentage in mucinous 
lestions 
Diagnosis Mean% Std. Deviation Std. error Range 
Benign 25.509 21.903 7.301 0.8-61.4 
Borderline 1.281 0.526 0.372 0.9-1.6 
Malignant 2.272 2.217 0.991 0.8-5.9 
 
The proportion of DNA-aneuploid cells in the 
tumours increased as the nuclear area increased. 
There is significant positive correlation between mean 
percentage aneuploid value and mean nuclear area in 
all serous and mucinous groups. 
Table 5: Mean aneuploid (>4C) cell percentage in serous 
lesions 
Diagnosis Mean% Std. Deviation Std. error Range 
Benign 1.485 2.970 1.485 0.0-5.9 
Borderline 45.612 33.140 9.992 4.7-92.6 
Malignant 74.547 28.728 10.157 11.5-100.0 
 
 
Discussion 
  
The hypothesis on the progression of the 
ovarian epithelial tumours, benign to borderline to 
malignant, is still controversial [21]. Tumour 
progression occurs mainly by dissemination through 
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peritoneum resulting in relatively low-symptomatic 
disease [9]. The 5-year survival rate of women with 
ovarian cancer is approximately 40% and has not 
significantly changed over the last two decades, 
despite advances in treatment [22]. 
Table 6: Mean aneuploid (>4C) cell percentage in mucinous 
lesions 
Diagnosis Mean% Std. Deviation Std. error Range 
Benign 13.209 16.037 5.345 0.8-45.2 
Borderline 63.678 11.629 8.223 55.4-71.9 
Malignant 68.433 26.306 11.764 28.2-99.0 
 
Morphologic studies alone cannot make a 
definite distinction between benignity and malignancy, 
nor can they identify all precancerous lesions. A 
prominent hallmark of most human cancer is 
aneuploidy, which means having an abnormal number 
of chromosomes in a cell; like having 45 or 47 
chromosomes in a cell, when 46 is expected. 
Aneuploidy originates during cell division, when 
chromosomes do not separate efficiently between 
cells [23]. Aneuploidy is a result of the chromosomal 
instability of cancer cells and is thought to contribute 
to the initiation and progression of most carcinomas 
[15]. Aghmesheh et al, 2015 [24] stated that higher 
risk for aneuploidy in ovarian tumours was associated 
with BRCA1 mutations near the N- terminal.  
Table 7: Mean nuclear area in serous lesions 
Diagnosis Mean% Std. Deviation Std. error Range 
Serous benign 26.191 4.335 2.167 23.8-32.6 
Serous borderline 45.619 11.554 3.483 30.2-64.4 
Serous malignant 67.634 17.288 6.112 36.0-88.6 
 
The prognostic significance of DNA ploidy 
remains controversial in ovarian cancer. A number of 
studies on DNA aneuploidy showed that DNA 
aneuploidy can be of independent prognostic value 
[14, 25, 26]. Other studies were unable to prove the 
prognostic value of DNA aneuploidy [27, 28]. Our 
work studied DNA ploidy and nuclear area 
measurements in ovarian epithelial serous and 
mucinous tumours; benign, borderline and malignant.  
Table 8: Mean nuclear area in mucinous lesion 
Diagnosis Mean% Std. Deviation Std. error Range 
Mucinous benign 35.753 7.772 2.590 25.5-46.2 
Mucinous borderline 51.759 6.499 4.595 47.1-56.3 
Mucinous malignant 56.982 15.672 7.008 42.3-81.9 
 
The current study included 40 cases of 
ovarian surface epithelial tumours, 23 (57.5%) serous 
and 17 (42.5%) mucinous with benign, borderline and 
malignant lesions. This result agreed with that of 
Demirel et al, 1996 [18]; who found that serous 
tumours comprised the majority (74%) of their cases; 
the remainder were either mucinous or endometrioid 
tumors.  
Our results showed that all serous and six out 
of nine (66%) of mucinous benign tumors were 
diploid. Diploid means having a pair of each type of 
chromosomes in a cell; one derived from each parent; 
so that the basic number of chromosomes in a 
somatic cell is doubled. In the normal, nearly, all 
somatic cells in the human body are diploid. Our study 
indicated that all serous benign tumours and the 
majority of mucinous benign tumours, proved to be 
diploid and thus, simulate the normal, and mostly 
follow an innocent course. This also agrees with 
Griffiths et al, 1993 [29]; who found that 55 out of their 
56 cases of benign serous and mucinous ovarian 
cystadenomas were diploid. 
0
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Figure 4: Scatter plot 1 showing positive correlation between 
aneuploid value and nuclear area in serous groups (left). Scatter 
plot 2 showing positive correlation between aneuploid value and 
nuclear area in mucinous groups (right) 
 
In our work, the percentage of diploid cells 
was significantly higher in the benign than in both 
borderline and malignant serous and mucinous 
lesions (P value < 0.05). These results came in 
accordance with those of Kallioniemi et al, 1988 [30]; 
who analyzed nuclear DNA content from ovarian 
tumours by flow cytometry and compared the results 
with the clinicopathological features of the tumours. 
On the basis of these clinicopathological correlations, 
it appeared that DNA ploidy and nuclear DNA content 
reflected benign behaviour of some ovarian tumours 
(diploid with high pecentage of diploid cells), and also 
reflected the malignant potential of other ovarian 
tumours (aneuploid); according to each case specific 
data, and thus complemented the routine 
histopathological evaluation. 
Our study showed that three out of nine 
mucinous benign tumours were tetraploid indicating 
possible progression to aneuploidy. Castedo et al, 
2012 [31] stated that tetraploidy has been observed in 
the early stages of cancer, including not only ovarian 
cancer, but also cervical, colorectal, esophageal, 
mammary and other cancers. Tetraploid cells exhibit 
fitness whenever there is DNA damage. This may 
increase their survival during tumourigenesis and after 
anticancer chemotherapies. Also, tetraploid cells can 
undergo subsequent depolyploidization .This finding 
of tetraploidy necessitates extensive and exhaustive 
gross sampling in our mucinous ovarian tumour 
specimens, even the benign ones; in order not to miss 
any hidden focus of occult or impending transition to 
borderline and/ or malignant change. 
All serous and mucinous malignant tumours in 
our study were aneuploid. This agrees with Pradhan 
et al, 2009 [32] who showed that Grades 2 and 3 
serous adenocarcinomas were more often (80%) 
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aneuploid. High grade carcinomas showing more 
aneuploidy than low grade ones, reveals the 
association between aneuploidy and high grades, and 
consequently the association between aneuploidy and 
aggressiveness. Kimmig et al, 2002 [33] revealed that 
DNA ploidy was valuable in predicting clinical 
outcome of patients with advanced cancer, its value 
was either similar to, or even more than that of 
residual disease following surgery. 
Nine of eleven (81.8%) serous and all 
mucinous borderline tumours included in our study 
had an aneuploid DNA content and hence an 
aggressive behaviour which prompts exhaustive 
sampling of these tumours and close follow up of the 
patients; for rapid intervention. However other studies 
evaluated the DNA content of borderline ovarian 
lesions showing that (96%) of the cases were diploid 
and only 1 case (4%) was aneuploid [34]. Another 
study on borderline lesions found that (83.3%) of the 
cases were diploid, while (16.7%) showed aneuploid 
stemlines [18]. Ovarian borderline tumours included in 
our study, showing aneuploidy, may indicate their 
aggressiveness, thus addressing the issue of the 
necessity for rapid intervention. The variation in 
morphology, in this gray zone of histopathology, 
reflecting variation in biologic behaviour, does not only 
exist in borderline ovarian tumours, but also appears 
in colonic lesions especially adenomas where 
according to Gamal el Din et al., 2014 [35] mild 
dysplasia was seen in 26.7%, moderate dysplasia 
was seen in 33.3%, while marked dysplasia was 
observed in 40% of their colonic adenoma cases.  
Our results showed, in serous lesions, a 
highly significant difference in the mean percentage of 
aneuploid cells between benign (1.5%), borderline 
(45.6%) and malignant (74.5%) (p = 0.0001). This 
agrees with Karabiowska et al, 2004 [15] who found 
highly significant differences between borderline and 
malignant lesions as regards DNA ploidy. Thus, the 
percentage of aneuploid cells may play a role in 
distinction between benign, borderline and malignant 
serous ovarian lesions. Also, Cohen, 1996 [36] 
showed that DNA aneuploidy is an independent 
negative prognostic factor, not only in ovarian 
carcinoma, but also in malignant melanoma, small cell 
carcinoma of the lung, esophageal, endometrial, 
prostatic, urinary bladder, and papillary thyroid 
carcinoma. 
Our results showed, in mucinous lesions, 
highly significant differences in the mean percentage 
of aneuploid cells between benign (13.2%) and both 
borderline (63.7%) and malignant (68.4%) groups (p = 
0.0001); thus agreeing with Karabiowska et al, 2004 
[15]. The mean aneuploid value, in our work, was 
higher in malignant mucinous than in borderline 
mucinous neoplasms, though not statistically 
significant.  
The frequency of DNA aneuploidy in ovarian 
cancer varies widely in the literature. This discrepancy 
in the results may be due to different methodologies 
(fresh versus paraffin embedded samples or flow 
cytometry versus photocytometry). Also, fixation 
process, handling of samples for DNA analysis, 
criteria from histograms, interpretation and 
intratumoural DNA heterogeneity might explain the 
differences in the results. 
We found significant differences in the nuclear 
area between serous benign, borderline and 
malignant groups. This came in concordance with 
Stemberger- Papic et al, 2006 [37] who declared that 
there were significant differences as regards nuclear 
area between benign, borderline and malignant 
serous ovarian tumours, being highest in malignant 
lesions. Our study also showed significant difference 
in the nuclear area between mucinous benign and 
malignant groups, being highest in the malignant 
group. Differences were also found in the nuclear area 
between borderline and malignant mucinous groups 
though not statistically significant. In this context, 
Versa Ostojic et al, 2008 [38] found differences in the 
nuclear area between borderline and malignant 
mucinous ovarian tumours to the extent to be able to 
differentiate between them, nuclear area being 
highest in the malignant group. Also, Zeimet et al, 
2011 [39] revealed prognostic relevance of nuclear 
area in ovarian mucinous cancer, and demonstrated 
correlation between nuclear area morphometric 
changes and early cancer genome DNA 
hypomethylation. 
Our study showed significant positive 
correlation between DNA content and nuclear area in 
all serous and mucinous groups. These results came 
similar to those of Veerman et al, 2009 [19] who also 
showed that DNA ploidy and MNA (Mean Nuclear 
Area) were of significant prognostic value. Also, 
Lassus et al, 2011 [40] stated that DNA aneuploidy is 
a strong predictor of poor prognosis in serous ovarian 
carcinoma. 
From this study, we suggest that nuclear 
morphometry (nuclear area measurement) and DNA 
cytometry (DNA ploidy studies), combined together 
may act as biomarkers and as adjuncts to 
histopathology; in ovarian surface epithelial, serous 
and mucinous benign, borderline and malignant 
neoplasms. They can segregate borderline tumours 
into aggressive aneuploid ones and others that will 
pursue a more innocent, rather indolent course. 
Identified patients with aggressive tumours need to be 
properly and early managed. This will, hopefully, lead 
to better therapy results. We suggest that more 
research work as regards ploidy-related parameters 
and morphometric measurements would be applied to 
a larger sample size of ovarian tumours. Once 
consistent results obtained, we suggest that DNA 
ploidy cytometry and nuclear area morphometry, 
evaluated by the image analyzer, would routinely be 
assessed in ovarian borderline surface epithelial 
serous and mucinous tumour cases. 
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